S. McGovern , J. Johnson , D. Luo , K. Nguyen , M. McAleer , A. Paulino , D. Grosshans , P. Baxter , W. Zaky , P. Thall , A. Mahajan
{"title":"A Prospective Study of Conventionally Fractionated Dose Constraints for Reirradiation of Primary Brain Tumors in Children","authors":"S. McGovern , J. Johnson , D. Luo , K. Nguyen , M. McAleer , A. Paulino , D. Grosshans , P. Baxter , W. Zaky , P. Thall , A. Mahajan","doi":"10.1016/j.ijrobp.2024.11.049","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><div>Reirradiation is increasingly considered for recurrent pediatric brain tumors, but dosimetric guidelines are lacking. To identify composite dose-volume constraints for reirradiation of recurrent brain tumors in children, a prospective trial was conducted.</div></div><div><h3>Methods</h3><div>Nine children with recurrent brain tumors previously treated with radiation were prospectively reirradiated. Three had GBM, two had AT/RT, and one each had ependymoma, NGGCT, medulloblastoma, or meningioma. For all patients, DICOM format records of their prior radiation (RT1) fields were obtained and deformed onto the CT simulation for their second course of radiation (RT2). Conventionally fractionated treatment plans for RT2 satisfied dose constraints for RT2 alone and the composite sum of both courses (RT1+RT2). The primary endpoint was the rate of symptomatic brain necrosis at 6 months after RT2.</div></div><div><h3>Results</h3><div>Median age at RT2 was 9.7y (range, 2.9 -6.8 y). Median interval between RT1 and RT2 was 19 months (range, 7–82 months). Treatment modality for RT2 was VMAT for seven patients and proton therapy for two patients. Median prescription dose for RT2 was 45 Gy (range, 30.6-60 Gy). Five patients were evaluable for the primary endpoint; none had symptomatic brain necrosis at 6 months after RT2. Four patients were not evaluble at 6 months due to death (n=2) or transition to hospice (n=2) by 6 months, all due to progression of disease. Median overall survival from RT2 start for all patients was 10.7 months (range, 5.2-46.4 months).</div></div><div><h3>Conclusions</h3><div>This prospective study suggests that conventionally fractionated reirradiation for recurrent brain tumors in children may be performed safely. These results provide a starting point for development of dose-volume constraints for pediatric brain reirradiation. Advanced technologies such as proton therapy may allow for reirradiation dose escalation while minimizing dose to surrounding critical structures.</div></div>","PeriodicalId":14215,"journal":{"name":"International Journal of Radiation Oncology Biology Physics","volume":"121 3","pages":"Pages e13-e14"},"PeriodicalIF":6.4000,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Radiation Oncology Biology Physics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S036030162403623X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective
Reirradiation is increasingly considered for recurrent pediatric brain tumors, but dosimetric guidelines are lacking. To identify composite dose-volume constraints for reirradiation of recurrent brain tumors in children, a prospective trial was conducted.
Methods
Nine children with recurrent brain tumors previously treated with radiation were prospectively reirradiated. Three had GBM, two had AT/RT, and one each had ependymoma, NGGCT, medulloblastoma, or meningioma. For all patients, DICOM format records of their prior radiation (RT1) fields were obtained and deformed onto the CT simulation for their second course of radiation (RT2). Conventionally fractionated treatment plans for RT2 satisfied dose constraints for RT2 alone and the composite sum of both courses (RT1+RT2). The primary endpoint was the rate of symptomatic brain necrosis at 6 months after RT2.
Results
Median age at RT2 was 9.7y (range, 2.9 -6.8 y). Median interval between RT1 and RT2 was 19 months (range, 7–82 months). Treatment modality for RT2 was VMAT for seven patients and proton therapy for two patients. Median prescription dose for RT2 was 45 Gy (range, 30.6-60 Gy). Five patients were evaluable for the primary endpoint; none had symptomatic brain necrosis at 6 months after RT2. Four patients were not evaluble at 6 months due to death (n=2) or transition to hospice (n=2) by 6 months, all due to progression of disease. Median overall survival from RT2 start for all patients was 10.7 months (range, 5.2-46.4 months).
Conclusions
This prospective study suggests that conventionally fractionated reirradiation for recurrent brain tumors in children may be performed safely. These results provide a starting point for development of dose-volume constraints for pediatric brain reirradiation. Advanced technologies such as proton therapy may allow for reirradiation dose escalation while minimizing dose to surrounding critical structures.
期刊介绍:
International Journal of Radiation Oncology • Biology • Physics (IJROBP), known in the field as the Red Journal, publishes original laboratory and clinical investigations related to radiation oncology, radiation biology, medical physics, and both education and health policy as it relates to the field.
This journal has a particular interest in original contributions of the following types: prospective clinical trials, outcomes research, and large database interrogation. In addition, it seeks reports of high-impact innovations in single or combined modality treatment, tumor sensitization, normal tissue protection (including both precision avoidance and pharmacologic means), brachytherapy, particle irradiation, and cancer imaging. Technical advances related to dosimetry and conformal radiation treatment planning are of interest, as are basic science studies investigating tumor physiology and the molecular biology underlying cancer and normal tissue radiation response.